All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub is delighted to present a visual abstract representing key data pooled from the phase III Viale-a trial (NCT02993523) and a phase Ib trial (NCT02203773) investigating the efficacy and safety of venetoclax plus azacitidine and azacitidine monotherapy in treatment-naïve patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. This analysis will focus on isocitrate dehydrogenase (IDH) 1/2 mutational status; however, an overview of the Viale-a trial has been previously reported by the AML Hub, as well as articles on MRD response and TP53 mutational status.
To download this visual abstract, click below.Download here
Patients with poor risk cytogenetics and TP53wt treated with venetoclax and HMA show increases in overall survival compared to treatment with azacitidine only
Patients with acute myeloid leukemia (AML) with poor-risk cytogenetics show sub optimal...
MRD response in patients with newly diagnosed AML treated with venetoclax and azacitidine in the VIALE-A trial
The phase III VIALE-A trial (NCT02993523) is a randomized, double-blind study investigating the use of venetoclax + azacitidine (Ven+Aza)...
VIALE-A trial update | Venetoclax and azacitidine combination for the treatment of older patients with newly diagnosed AML
VIALE-A (NCT02993523) is a randomized, double-blind, multicenter, placebo-controlled phase III study that compares venetoclax...
Subscribe to get the best content related to AML delivered to your inbox